These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194 [TBL] [Abstract][Full Text] [Related]
6. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan. Pazdur R J Gastroenterol; 2000; 35 Suppl 12():131. PubMed ID: 10779234 [No Abstract] [Full Text] [Related]
8. Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. Kanbayashi Y; Ishikawa T; Kanazawa M; Nakajima Y; Tabuchi Y; Kawano R; Yoshioka T; Yoshida N; Hosokawa T; Takayama K; Taguchi T Med Oncol; 2018 Apr; 35(6):82. PubMed ID: 29705823 [TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245 [No Abstract] [Full Text] [Related]
10. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Merrouche Y; Mugneret F; Cahn JY Ann Oncol; 2006 Jun; 17(6):1025-6. PubMed ID: 16293675 [No Abstract] [Full Text] [Related]
11. Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer. Tsuboya A; Fujita KI; Kubota Y; Ishida H; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y Int J Clin Oncol; 2019 Feb; 24(2):222-230. PubMed ID: 30244364 [TBL] [Abstract][Full Text] [Related]
12. CPT-11-induced cholinergic effects in cancer patients. Gandia D; Abigerges D; Armand JP; Chabot G; Da Costa L; De Forni M; Mathieu-Boue A; Herait P J Clin Oncol; 1993 Jan; 11(1):196-7. PubMed ID: 8418235 [No Abstract] [Full Text] [Related]
13. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295 [TBL] [Abstract][Full Text] [Related]
14. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824 [TBL] [Abstract][Full Text] [Related]
15. Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen. Schwartzman AD; Sethi R; Smith R Clin Colorectal Cancer; 2013 Jun; 12(2):136-9. PubMed ID: 23098664 [No Abstract] [Full Text] [Related]
16. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212 [TBL] [Abstract][Full Text] [Related]
17. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715 [TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Said R; Kurzrock R; Naing A; Hong DS; Fu S; Piha-Paul SA; Wheler JJ; Janku F; Kee BK; Bidyasar S; Lim J; Wallace M; Tsimberidou AM Invest New Drugs; 2015 Aug; 33(4):911-20. PubMed ID: 25990659 [TBL] [Abstract][Full Text] [Related]
19. Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer. Chico IM; Pazdur R Clin Colorectal Cancer; 2002 May; 2(1):11-2. PubMed ID: 12453329 [No Abstract] [Full Text] [Related]
20. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer. Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]